Belgian biotech Quidditas Therapeutics has raised €2.62M to develop its GREAT technology platform, which enables precise genetic recombination of any length at any genomic location, overcoming limitations of current CRISPR systems.

Teplizumab has received FDA approval as the world's first disease-modifying therapy for type 1 diabetes, delaying onset by an average of three years in high-risk individuals aged eight and older.

Contineum Therapeutics expects topline data from its PIPE-791 Phase 1b PET trial in Q2 2025 and PIPE-307 Phase 2 VISTA trial for relapsing-remitting multiple sclerosis in H2 2025, affirming its clinical development timeline.

The FDA has granted accelerated approval to zanidatamab-hrii (Ziihera) for previously treated, unresectable or metastatic HER2-positive biliary tract cancer.

The FDA has granted accelerated approval to Ziihera (zanidatamab-hrii) for adults with previously treated, unresectable or metastatic HER2-positive biliary tract cancer.

NRx Pharmaceuticals is on track to file NDAs for NRX-100 (IV Ketamine) for suicidal ideation in depression and NRX-101 (Oral D-Cycloserine/Lurasidone) for bipolar depression with suicidality by year-end 2024.

GH Research reported a net loss of $12.1 million in Q3, driven by increased R&D spending on clinical trials for its 5-MeO-DMT therapies.

GSK's Blenrep, combined with chemotherapy and a steroid, reduced the risk of death by 42% compared to a standard-of-care treatment in relapsed or refractory multiple myeloma.

A recent study published in *Cancers* indicates that switching between rituximab biosimilars does not elevate the risk of adverse reactions in patients with hematological diseases.

The European Medicines Agency (EMA) has approved Leqembi for treating early-stage Alzheimer's disease, reversing an earlier rejection due to concerns about side effects.

Real-world data from the CrescNet registry showed that children treated with Voxzogo experienced an average height increase of 6.36 cm after 12 months.

Embryonal tumor with multi-layered rosettes (ETMR) is a rare, aggressive brain cancer in children, lacking a standard treatment protocol, making clinical trials a crucial option.

Researchers have discovered that SARS-CoV-2 RNA can trigger the development of inducible nonclassical monocytes (I-NCMs), a unique type of immune cell with anti-cancer properties.

A Phase II study reveals that infigratinib, an oral medication, significantly increases height in children with achondroplasia, the most common form of dwarfism.

Trastuzumab duocarmazine (T-Duo) significantly improved progression-free survival in patients with advanced HER2-positive metastatic breast cancer compared to physician's choice of treatment.

The CHMP has recommended Tagrisso (osimertinib) for EU approval to treat locally advanced, unresectable non-small cell lung cancer (NSCLC) with specific EGFR mutations.

Zydus Healthcare will conduct a Phase III clinical trial for its fixed-dose combination of glycopyrrolate and indacaterol metered-dose inhalation, as recommended by the CDSCO panel.

The FDA has approved icobrain aria, an AI-driven software, to assist in detecting ARIA (Amyloid-Related Imaging Abnormalities) in MRI scans of patients undergoing amyloid immunotherapy.

Researchers have developed injectable oxygen microbubbles for rapid oxygen delivery during critical moments of cardiac or respiratory arrest, addressing the limitations of traditional methods.

Zerlasiran, a novel siRNA, significantly reduced time-averaged lipoprotein(a) levels by over 80% in a Phase 2 trial, offering a potential treatment for elevated Lp(a).